Curated News
By: NewsRamp Editorial Staff
April 28, 2025
Silo Pharma Files Patent for Intranasal Compound SPC-14 Targeting Alzheimer’s Symptoms
TLDR
- Silo Pharma gains competitive edge with patent filing for SPC-14 targeting Alzheimer's cognitive symptoms
- SPC-14 patent application filed by Silo Pharma focuses on NDMAR and serotonin 5-HT4 mechanisms for cognitive memory improvement
- Silo Pharma's patent for SPC-14 offers hope for improved treatment of Alzheimer's, enhancing quality of life for patients
- Silo Pharma's novel intranasal compound SPC-14 shows promise in enhancing cognitive memory function through innovative mechanisms
Impact - Why it Matters
This news matters as it highlights Silo Pharma's innovative approach in developing novel therapeutics for underserved conditions like Alzheimer's disease. The filing of the patent for SPC-14 signifies a significant step towards addressing cognitive and neuropsychiatric symptoms in Alzheimer’s patients, potentially offering hope for improved treatment options in the future.
Summary
Silo Pharma (NASDAQ: SILO) announced the filing of a patent application with the U.S. Patent and Trademark Office for SPC-14, a novel intranasal compound exclusively licensed from Columbia University targeting cognitive and neuropsychiatric symptoms in Alzheimer’s disease. The patent covers SPC-14’s mechanism of action focused on glutamate receptor NDMAR and serotonin 5-HT4, with preclinical studies demonstrating potential improvements in cognitive memory function. The filing supports Silo’s broader intellectual property strategy for protecting its drug platforms.
Source Statement
This curated news summary relied on this press release disributed by InvestorBrandNetwork (IBN). Read the source press release here, Silo Pharma Files Patent for Intranasal Compound SPC-14 Targeting Alzheimer’s Symptoms
